Compositions and methods of treating retinal disease
Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.
1. A pharmaceutical composition comprising a compound selected from the group consisting of:
and a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
2. A method of treating macular degeneration, comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of:
and a pharmaceutically acceptable salt thereof.
3. The method of claim 2 , wherein the macular degeneration is age related macular degeneration (AMD).
4. The method of claim 3 , wherein the AMD is wet AMD.
5. The method of claim 3 , wherein the AMD is dry AMD.
6. The method of claim 2 , wherein the macular degeneration is Stargardt's disease.